Inhibition of placenta growth factor with TB-403: A novel antiangiogenic cancer therapy

Expert Opinion on Biological Therapy

Volumn 12, Issue 6, 2012, Pages 795-804

  Nielsen, Dorte Lisbet ^a   Sengeløv, Lisa ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antiangiogenic therapy; Placenta growth factor; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; PLACENTAL GROWTH FACTOR; RO 5323441; SORAFENIB; TB 403; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; DRUG HALF LIFE; DYSPNEA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; LIVER CELL CARCINOMA; LUNG EMBOLISM; LYMPHANGIOGENESIS; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NAUSEA; NECK PAIN; NEOPLASM; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REVIEW; UPPER GASTROINTESTINAL BLEEDING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84861307333     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.679655     Document Type: Review

References (95)

1. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: Mechanisms and therapeutic implications. EXS 2006;96:223-268
2. Gao D, Nolan D, McDonnell K, et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumour growth and metastatic progression. Biochim Biophys Acta 2009;1796(1):33-40
3. Birk DM, Barbato J, Mureebe L, Chaer RA. Current insight on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 2008;42(6):517-530
4. Van Meter ME, Kim ES. Bevacizumab: Current updates in treatment. Curr Opin Oncol 2010;22(6):586-591
5. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 2010;22(4):374-380
6. Bertino EM, Otterson GA. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 2010; [Epub ahead of print]
7. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 2010;46(8):1323-1332
8. Reck M. Examining the safety profile of angiogenesis inhibitors: Implications for clinical practice. Target Oncol 2010; [Epub ahead of print]
9. Staton CA, Brown NJ, Reed MWR. Current status and future prospects for anti-angiogenic therapies in cancer. Expert Opin 2009;4(9):961-979
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-676
11. Roskoski R Jr. VEGF receptor protein-tyrosine kinases: Structure and regulation. Biochem Biophys Res Commun 2008;375(3):287-291
12. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21(2):154-165
13. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40
14. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009;2(59):re1
15. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39(5):469-478
16. Hiratsuka S, Maru Y, Okada A, et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001;61(3):1207-1213
17. Murakami M, Iwai S, Hiratsuka S, et al. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006;108(6):1849-1856
18. Kami J, Muranaka K, Yanagi Y, et al. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. Jpn J Ophthalmol 2008;52(2):91-8
19. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88(20):9267-9271
20. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997;76(4):517-531
21. Odorisio T, Schietroma C, Zaccaria ML, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002;115(Pt 12):2559-2567
22. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1(7):1356-1370
23. Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62(10):2749-2752
24. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006;20(9):1495-1497
25. Tarallo V, Vesci L, Capasso O, et al. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 2010;70(5):1804-1813
26. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive hematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005;438(7069):820-827
27. Taylor AP, Leon E, Goldenberg DM. Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Br J Cancer 2010;103(1):82-9
28. Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007;6(2):524-531
29. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGF1/Flt1): A dual regulator for angiogenesis. Angiogenesis 2006;9(4):225-230
30. Fisher C, Mazzone M, Jonckx B, Cameliet P. FLT1 and its ligands VEGFB and PIGF: Drug targets for antiangiogenic therapy? Nat Rev Cancer 2008;8(12):942-956
31. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269(41):25646- 5654
32. Marcellini M, De Luca N, Riccioni T, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placeta growth factor. Am J Pathol 2006;169(2):643-654
33. Roy H, Bhardwaj S, Babu M, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of vascular endothelial growth factor-A. Hum Gene Ther 2005;16(12):1422-1428
34. Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 2006;66(8):3971-3977
35. Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 2006;20(9):1495-1497
36. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269(41):25646- 5654
37. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996;271(6):3154-3162
38. Dawson MR, Duda DG, Chae SS, et al. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One 2009;4(9):e6525
39. Bais C, Wu X, Yao J, et al. PIGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141(1):166-177
40. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39(5):469-478
41. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8(8):831-840
42. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FTL-1) in nephroblastoma. J Clin Pathol 2003;56(2):107-113
43. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59(4):520-529
44. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FTL-1 and FTL-4 during neoplastic progression of human colonic mucusa. Int J Cancer 2000;86(2):174-181
45. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995;11(8):1569-1579
46. Nomura M, Yamagishi S, Harada S, et al. Placenta growth factor (PlGF) mRNA expression in brain tumors. J Neurooncol 1998;40(2):123-130
47. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54(15):4233-4237
48. Zhang L, Chen J, Ke Y, et al. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005;3:68-79
49. Kodama J, Seki N, Tokumo K, et al. Placenta growth factor is abundantly expressed in human cervical squamous cell carcinoma. Eur J Gynaecol Oncol 1997;18(6):508-510
50. Chen CN, Hsieh FJ, Cheng YM, et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004;213(1):73-82
51. Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005;54(5):666-672
52. Wei SC, Liang JT, Tsao PN, et al. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum 2009;52(9):1630-1636
53. Cheng SJ, Lee JJ, Kok SH, et al. Expression of placenta growth factor: An independent factor for prediction of progression and prognosis of oral cancer. Head Neck 2010;32(10):1363-1369
54. Escudero-Esparza A, Martin TA, Davies ML, Jiang WG. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 2009;6(4):239-246
55. Escudero-Esparza A, Martin TA, Douglas-Jones A, et al. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: Prognostic significance. Oncol Rep 2010;23(2):537-544
56. Ho MC, Chen CN, Lee H, et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007;250(2):237-249
57. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743-3748
58. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95
59. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28(3):453-459
60. Xu HX, Zhu XD, Zhuang PY, et al. Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer 2011;128(7):1559-1569
61. Nagaoka S, Yoshida T, Akiyoshi J, et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 2010;23(6):1647-1654
62. Matsumoto K, Suzuki K, Koike H, et al. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. Anticancer Res 2003;23(5A):3767-3773
63. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131(3):463-475
64. Loges S, Schmidt T, Carmeliet P. Antimyeloangiogenic therapy for cancer inhibiting PIGF. Clin Cancer Res 2009;15(11):3648-3653
65. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8(12):942-956
66. Dawson MR, Duda DG, Fukumura D, Jain RK. VEGFR1-activity-independent metastasis formation. Nature 2009;461(7262):E4-discussion E5
67. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7(11):1194-1201
68. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
69. Davis-Smyth T, Chen H, Park J, et al. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996;15(18):4919-4927
70. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380(6573):439-442
71. Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010;141(1):178-190
72. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16(1):67-78
73. Coenegrachts L, Maes C, Torrekens S, et al. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 2010;70(16):6537-6547
74. Schmidt T, Kharabi Masouleh B, Loges S, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1 (+) leukemia. Cancer Cell 2011;19(6):740-753
75. Roncal C, Buysschaert I, Gerdes N, et al. Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res 2010;86(1):29-36
76. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7(5):575-583
77. Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403: A first-in-human, phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther 2011;33(9):1142-1149
78. Rizzo C, Yin Yin X, Packman K, et al. RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PIGF-induced VEGFr-1 phosphorylation in vitro and tumor growth in vivo. Cancer Res 2010;70(8 Suppl 1):1370
79. Lassen U, Nielsen DL, Sørensen M, et al. A phase I, dose escalation study of TB-403, a monoclonal antibody directed against PIGF, in patients with advanced solid tumours. Br J Cancer 2012;106:678-684
80. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 2012; [Epub ahead of print]
81. Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19-30
82. Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22(8):1178-1182
83. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 2010;10(7):505-514
84. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-5334
85. Hayes DF. Bevacizumab treatment for solid tumors. Boon or bust? JAMA 2011;305(5):506-508
86. Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Biol Rev 2009;19(5):310-317
87. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010;21(1):21-6
88. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
89. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438(7070):932-936
90. Taylor AP, Rodriguez M, Adams K, et al. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: Potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003;105(2):158-164
91. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473(7347):298-307
92. Yanagisawa M, Yorozu K, Kurasawa M, et al. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010;21(7):687-694
93. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: Rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008;5(9):521-530
94. Hurvitz SA, Pegram MD, Lin L-S, et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 2009;69(Suppl):abstract 6094
95. Schmidt T, Carmeliet P. Angiogenesis: A target in solid tumors, also in leukemia? Hematol Am Soc Hematol Educ Program 2011;2011:1-8